Cargando…
Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel dise...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024211/ https://www.ncbi.nlm.nih.gov/pubmed/35464463 http://dx.doi.org/10.3389/fimmu.2022.880190 |
_version_ | 1784690523028586496 |
---|---|
author | Xu, Alexander M. Li, Dalin Ebinger, Joseph E. Mengesha, Emebet Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Joung, Sandy Botwin, Gregory J. Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Prostko, John C. Frias, Edwin C. Stewart, James L. Horizon, Arash A. Merin, Noah Sobhani, Kimia Figueiredo, Jane C. Cheng, Susan Kaplan, Ian M. McGovern, Dermot P. B. Merchant, Akil Melmed, Gil Y. Braun, Jonathan |
author_facet | Xu, Alexander M. Li, Dalin Ebinger, Joseph E. Mengesha, Emebet Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Joung, Sandy Botwin, Gregory J. Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Prostko, John C. Frias, Edwin C. Stewart, James L. Horizon, Arash A. Merin, Noah Sobhani, Kimia Figueiredo, Jane C. Cheng, Susan Kaplan, Ian M. McGovern, Dermot P. B. Merchant, Akil Melmed, Gil Y. Braun, Jonathan |
author_sort | Xu, Alexander M. |
collection | PubMed |
description | T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel disease (IBD), a spectrum of chronic intestinal inflammatory diseases usually requiring immunomodulatory treatment, the T-cell response has not been well characterized. Understanding the patient factors that result in strong vaccination responses is critical to guiding vaccination schedules and identifying mechanisms of T-cell responses in IBD and other immune-mediated conditions. Here we used T-cell receptor sequencing to show that T-cell responses in an IBD cohort were influenced by demographic and immune factors, relative to a control cohort of health care workers (HCWs). Subjects were sampled at the time of SARS-CoV-2 vaccination, and longitudinally afterwards; TCR Vβ gene repertoires were sequenced and analyzed for COVID-19-specific clones. We observed significant differences in the overall strength of the T-cell response by age and vaccine type. We further stratified the T-cell response into Class-I- and Class-II-specific responses, showing that Ad26.COV2.S vector vaccine induced Class-I-biased T-cell responses, whereas mRNA vaccine types led to different responses, with mRNA-1273 vaccine inducing a more Class-I-deficient T-cell response compared to BNT162b2. Finally, we showed that these T-cell patterns were consistent with antibody levels from the same patients. Our results account for the surprising success of vaccination in nominally immuno-compromised IBD patients, while suggesting that a subset of IBD patients prone to deficiencies in T-cell response may warrant enhanced booster protocols. |
format | Online Article Text |
id | pubmed-9024211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90242112022-04-23 Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease Xu, Alexander M. Li, Dalin Ebinger, Joseph E. Mengesha, Emebet Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Joung, Sandy Botwin, Gregory J. Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Prostko, John C. Frias, Edwin C. Stewart, James L. Horizon, Arash A. Merin, Noah Sobhani, Kimia Figueiredo, Jane C. Cheng, Susan Kaplan, Ian M. McGovern, Dermot P. B. Merchant, Akil Melmed, Gil Y. Braun, Jonathan Front Immunol Immunology T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after infection or vaccination. For patients with inflammatory bowel disease (IBD), a spectrum of chronic intestinal inflammatory diseases usually requiring immunomodulatory treatment, the T-cell response has not been well characterized. Understanding the patient factors that result in strong vaccination responses is critical to guiding vaccination schedules and identifying mechanisms of T-cell responses in IBD and other immune-mediated conditions. Here we used T-cell receptor sequencing to show that T-cell responses in an IBD cohort were influenced by demographic and immune factors, relative to a control cohort of health care workers (HCWs). Subjects were sampled at the time of SARS-CoV-2 vaccination, and longitudinally afterwards; TCR Vβ gene repertoires were sequenced and analyzed for COVID-19-specific clones. We observed significant differences in the overall strength of the T-cell response by age and vaccine type. We further stratified the T-cell response into Class-I- and Class-II-specific responses, showing that Ad26.COV2.S vector vaccine induced Class-I-biased T-cell responses, whereas mRNA vaccine types led to different responses, with mRNA-1273 vaccine inducing a more Class-I-deficient T-cell response compared to BNT162b2. Finally, we showed that these T-cell patterns were consistent with antibody levels from the same patients. Our results account for the surprising success of vaccination in nominally immuno-compromised IBD patients, while suggesting that a subset of IBD patients prone to deficiencies in T-cell response may warrant enhanced booster protocols. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024211/ /pubmed/35464463 http://dx.doi.org/10.3389/fimmu.2022.880190 Text en Copyright © 2022 Xu, Li, Ebinger, Mengesha, Elyanow, Gittelman, Chapman, Joung, Botwin, Pozdnyakova, Debbas, Mujukian, Prostko, Frias, Stewart, Horizon, Merin, Sobhani, Figueiredo, Cheng, Kaplan, McGovern, Merchant, Melmed and Braun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Xu, Alexander M. Li, Dalin Ebinger, Joseph E. Mengesha, Emebet Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Joung, Sandy Botwin, Gregory J. Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Prostko, John C. Frias, Edwin C. Stewart, James L. Horizon, Arash A. Merin, Noah Sobhani, Kimia Figueiredo, Jane C. Cheng, Susan Kaplan, Ian M. McGovern, Dermot P. B. Merchant, Akil Melmed, Gil Y. Braun, Jonathan Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title | Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title_full | Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title_fullStr | Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title_full_unstemmed | Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title_short | Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease |
title_sort | differences in sars-cov-2 vaccine response dynamics between class-i- and class-ii-specific t-cell receptors in inflammatory bowel disease |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024211/ https://www.ncbi.nlm.nih.gov/pubmed/35464463 http://dx.doi.org/10.3389/fimmu.2022.880190 |
work_keys_str_mv | AT xualexanderm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT lidalin differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT ebingerjosephe differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT mengeshaemebet differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT elyanowrebecca differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT gittelmanrachelm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT chapmanheidi differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT joungsandy differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT botwingregoryj differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT pozdnyakovavaleriya differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT debbasphilip differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT mujukianangela differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT prostkojohnc differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT friasedwinc differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT stewartjamesl differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT horizonarasha differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT merinnoah differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT sobhanikimia differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT figueiredojanec differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT chengsusan differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT kaplanianm differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT mcgoverndermotpb differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT merchantakil differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT melmedgily differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease AT braunjonathan differencesinsarscov2vaccineresponsedynamicsbetweenclassiandclassiispecifictcellreceptorsininflammatoryboweldisease |